EP3062780A1 — Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
Assigned to Vestlandets Innovasjonsselskap AS · Expires 2016-09-07 · 10y expired
What this patent protects
The present invention relates in a first aspect to a therapeutically effective amount of a stimulator of the soluble guanylate cyclase and/or of an activator of the soluble guanylate cyclase for use in the treatment of chronic fatique syndrome (CFS) in a patient in need thereof. …
USPTO Abstract
The present invention relates in a first aspect to a therapeutically effective amount of a stimulator of the soluble guanylate cyclase and/or of an activator of the soluble guanylate cyclase for use in the treatment of chronic fatique syndrome (CFS) in a patient in need thereof. In a further aspect, the present invention relates to a combination of the stimulator and/or activator of the soluble guanylate cyclase with a B-cell depleting agent in the treatment of chronic fatique syndrome. In addition, a combination of stimulator and/or activator of the soluble guanylate cyclase with B-Cell depleting agent is described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds.
Drugs covered by this patent
- Adempas (RIOCIGUAT) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.